457,974 Shares in Alamar Biosciences, Inc. $ALMR Acquired by Wellington Management Group LLP

Wellington Management Group LLP purchased a new stake in shares of Alamar Biosciences, Inc. (NASDAQ:ALMR) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 457,974 shares of the company’s stock, valued at approximately $12,407,000.

Alamar Biosciences Price Performance

ALMR stock opened at $30.80 on Tuesday. The stock has a 50 day moving average of $28.72. Alamar Biosciences, Inc. has a fifty-two week low of $18.84 and a fifty-two week high of $38.54. The company has a quick ratio of 10.23, a current ratio of 11.85 and a debt-to-equity ratio of 0.03. The company has a market cap of $2.14 billion and a PE ratio of -15.71.

Alamar Biosciences (NASDAQ:ALMR) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.14. The firm had revenue of $29.43 million during the quarter. As a group, equities analysts expect that Alamar Biosciences, Inc. will post -1.19 earnings per share for the current fiscal year.

Analyst Ratings Changes

ALMR has been the topic of several research analyst reports. Weiss Ratings assumed coverage on Alamar Biosciences in a report on Tuesday, August 11th. They set a “sell (d+)” rating on the stock. Bank of America initiated coverage on Alamar Biosciences in a report on Tuesday, May 12th. They issued a “neutral” rating and a $27.00 price target for the company. Zacks Research upgraded shares of Alamar Biosciences to a “hold” rating in a research report on Wednesday, May 13th. Stifel Nicolaus increased their price objective on shares of Alamar Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a research report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $31.80.

Alamar Biosciences Profile

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.